COMMONWEALTH OF KENTUCKY
CABINET FOR HEALTH AND FAMILY SERVICES
DEPARTMENT FOR MEDICAID SERVICES
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING

NOTE: This special called meeting will be held virtually via Zoom webinar.
Thursday, November 18, 2021
1:00 P.M. to 4:00 P.M. (Eastern)

Access Information

<table>
<thead>
<tr>
<th>Smartphone/Web</th>
<th>Dial-In</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="https://magellanhealth.zoom.us/s/96678131651">https://magellanhealth.zoom.us/s/96678131651</a>&lt;br&gt;Webinar ID: 966 7813 1651&lt;br&gt;Password: 617843</td>
<td>+1 312 626 6799 (US Toll) OR +1 646 558 8656 (US Toll)</td>
</tr>
<tr>
<td></td>
<td>Webinar ID: 966 7813 1651&lt;br&gt;Passcode: 617843</td>
</tr>
</tbody>
</table>

AGENDA

I. Call to Order and Welcome

II. Executive Session (upon request)

III. Old Business
   a. Approval of Meeting Minutes

IV. New Business
   a. New Products to Market to be reviewed as single products:
      i. Brexafem® (Antifungals: Oral)
      ii. Kerendia® (Non-PDL drug class)
      iii. Verquvo® (Non-PDL drug class)

V. Therapeutic Classes with Recommended Changes
   a. Hypoglycemics, Incretin Mimetics/Enhancers
      i. Diabetes: DPP-4 Inhibitors
      ii. Diabetes: GLP-1 Receptor Agonists
   b. Pulmonary Arterial Hypertension (PAH) Agents
   c. Acne Agents, Topical
   d. Antipsoriatrics, Oral
   e. Antipsoriatrics, Topical
   f. Steroids, Topical
   g. Cytokine and CAM Antagonists (Immunomodulators)
   h. Ophthalmics, Glaucoma Agents
      i. Ophthalmic Beta Blockers
      ii. Ophthalmic Carbonic Anhydrase Inhibitors
      iii. Ophthalmic Combinations for Glaucoma
      iv. Ophthalmic Prostaglandin Agonists
      v. Ophthalmic Sympathomimetics
      vi. Ophthalmics, Glaucoma Agents (Other)

V. Consent Agenda
a. The following therapeutic classes have no changes recommended and may be voted on as a group under a consent agenda:

- Acne Agents, Oral
- Antibiotics, Topical
- Antifungals, Topical
- Antiparasitics, Topical
- Antivirals, Topical
- Rosacea Agents, Topical
- Antiemetics & Antivertigo Agents
  - Anti-Emetics: Other
  - Oral Anti-Emetics: 5-HT3 Antagonists
  - Oral Anti-Emetics: NK-1 Antagonists
  - Oral Anti-Emetics: Δ-9-THC Derivatives
- Antispasmodics/Anticholinergics
- Antiulcer protectants
- Bile salts
- GI motility agents
- H. pylori treatment
- Histamine II receptor blockers
  - H2Receptor Antagonists
- Laxatives and cathartics
- Proton pump inhibitors
- Ulcerative colitis agents
- Immunomodulators, atopic dermatitis
- Immunosuppressives, oral
  - Immunosuppressants
- Multiple sclerosis agents
- Spinal muscular atrophy
- Ophthalmics, allergic conjunctivitis
  - Ophthalmic antihistamines
  - Ophthalmic mast cells stabilizers
- Ophthalmics, anti-inflammatories
  - Ophthalmic NSAIDs
  - Ophthalmic anti-inflammatory steroids
- Ophthalmics, antibiotics-steroid combinations
- Ophthalmics, antibiotics
  - Ophthalmic quinolones
  - Ophthalmic antibiotics, non-quinolones
- Ophthalmics, antivirals
- Ophthalmic immunomodulators
- Ophthalmics, mydriatics & mydriatic combinations
- Ophthalmic vasoconstrictors
- Otic antibiotics
- Otics, anti-inflammatory agents
  - Otic anesthetics and anti-inflammatories

V. Adjournment

a. Schedule of Upcoming Meetings
   i. January 20, 2022
   ii. March 17, 2022
   iii. May 19, 2022
   iv. July 21, 2022

To view the most current Preferred Drug List (PDL) and Prior Authorization (PA) criteria please go to https://kyportal.magellanmedicaid.com/provider/public/home.xhtml.

PUBLIC SPEAKERS: If you would like to speak during the public session, please complete the Speaker Request Form located on the Committees/P&T tab of the Kentucky specific Magellan Medicaid Administration web portal at: https://kyportal.magellanmedicaid.com/provider/public/documents.xhtml.